Form 4: Akebia Therapeutics SVP, CFO, CBO & Treasurer Erik Ostrowski Reports Acquisition of 350,000 Shares and 500,000 Stock Options

Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, reports the acquisition of 350,000 shares of common stock and 500,000 stock options.

Summary

• On June 28, 2024, Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, acquired 350,000 shares of common stock.
• These shares were granted as restricted stock units (RSUs) under the company's 2023 Stock Incentive Plan.
• The RSUs will vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continued service with the Issuer.
• On the same date, Mr. Ostrowski also acquired 500,000 stock options with an exercise price of $1.02.
• These options were granted as an inducement for Mr. Ostrowski's employment with Akebia Therapeutics.
• The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal quarterly installments thereafter, subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reflects standard executive compensation practices, which are generally viewed favorably as they align management interests with shareholder value. There are no explicit negative indicators.

Positives

• The grant of RSUs and stock options to a key executive like the SVP, CFO, CBO & Treasurer can be seen as an incentive to align their interests with the company's long-term success.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the executive.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. The specific terms of the grants, such as vesting schedules and exercise prices, are often tailored to the individual and the company's specific circumstances.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation tools in the biotech industry.
• Vesting schedules of 3-4 years are typical to ensure long-term commitment.
• The size of the grant would need to be compared to grants made to executives in comparable roles at similar-sized biotech companies to assess its relative value.

Stakeholder Impact

• Shareholders: The equity grants could be viewed positively as aligning management's interests with the company's long-term success.
• Employees: The grants could signal confidence in the company's future and incentivize continued performance.

Key Dates